Helix BioPharma Corp. announced the opening of patient screening for the sixth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the fifth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.

The Phase I/II clinical study is an open-label study to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study commenced with a starting dose of 0.12 micrograms of L-DOS47 per kilogram of patient body weight in the first patient cohort. Patients to be enrolled in the sixth cohort will receive the next L-DOS47 dose level as planned in the study protocol, which is 0.78 micrograms of L-DOS47 per kilogram of patient body weight.